A Phase 2 interventional study of Rituximab and Chlorambucil in Lymphocytic Leukemia, Chronic, sponsored by Hoffmann-La Roche. Completed at 12 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-04-06.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 197 studies testing rituximab in Leukemia, Lymphocytic, Chronic, B-Cell — 3 open to participants now, 12 under way, 4 of them phase 3. Rituximab · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 197 studies testing rituximab in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 31st largest by enrollment of the 189 interventional ones that give a count, is one of 11 that started in 2007, is one of 119 in phase 2, and was the 83rd registered.
2,038 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →3 of the 197 studies testing rituximab in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
Paolo Caimi, MD · Sites in United States
Ages 18+
BeOne Medicines · Sites in United States, Argentina, Australia and 18 more countries
Ages 18+
Paolo Ghia · Sites in Italy
Ages 18–65
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
197 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 56 · Phase 2 138 · Phase 3 18 · Phase 4 2
First in 1997; this study’s year is marked. 11 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 39 across 1,605 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 39 across the 189 interventional studies. Of the 166 that completed or were terminated, 93 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 197 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche: 1 open now, 2 under way, none of them phase 3. Of 46 finished, 28 (61%) have results posted.
Among the 48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche, this one is the 18th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2007, is one of 13 in phase 2, and was the 4th registered.
Hoffmann-La Roche’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2003.
2 of the studies testing rituximab in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03467867Georgetown UniversityA Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL | 2026-12 |
| NCT04458610M.D. Anderson Cancer CenterZanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | 2027-05-26 |
Add all 2 to your calendar (.ics) → With an account.
Among the 197 studies testing rituximab in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among Hoffmann-La Roche’s 48 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
This single arm study will assess the safety and effect on response rate of a combination of rituximab and chlorambucil in previously untreated participants with B-cell chronic lymphocytic leukemia. Participants will receive 6 monthly cycles of combination treatment, followed by up to 6 cycles of chlorambucil alone. Rituximab will be administered on Day 1 of each cycle, at a dose of 375 milligrams per square meter (mg/m\^2) intravenously (IV) in Cycle 1, and 500 mg/m\^2 in subsequent cycles, and chlorambucil will be administered on Days 1-7 of each cycle at a dose of 10 mg/m\^2/day per oral (PO).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive combination therapy of rituximab plus chlorambucil for first 6 cycles and then chlorambucil alone for a maximum of 6 additional cycles.
Drug: Rituximab · Drug: Chlorambucil
375mg/m\^2 IV on Day 1 of Cycle 1; 500mg/m\^2 on Day 1 of Cycles 2-6.
Also known as: MabThera, Rituxan
10 mg/m\^2/day PO on Days 1 to 7 of each cycle for a maximum of 12 cycles.
Percentage of Participants With Treatment-Emergent Adverse Events (AEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 56 days from the beginning of the last treatment cycle that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs as well as non-serious AEs.
Time frame: First administration of study treatment up to 56 days after the beginning of the last treatment cycle (up to 365 days)
Percentage of Participants With Best Overall Response (BOR) of Clinical CR or Confirmed CR
Clinical CR was achieved if all of the following criteria were met: a)Absence of lymphadenopathy (LD) by physical examination (PE) and Computed Tomography (CT) scan (all lymph nodes less than \[\<\] 1.5 centimeters \[cm\] in diameter), b)No hepatomegaly (HM)/splenomegaly (SM) by PE/CT scan, c)Absence of B symptoms (unexplained fever greater than \[\>\] 38 degrees \[°\] Centigrade \[C\], drenching night sweats/\>10 percent \[%\] body weight loss in the last 6 months), d)Normal Complete Blood Count (CBC) (i. Leukocytes (Leuk) greater than or equal to \[≥\] 1.5×10\^9 per liter (/L), ii. Platelets (Plat) \>100×10\^9/L, and iii. Haemoglobin (Hb) \>11.0 grams per deciliter \[g/dL\]) and e)Once clinical, radiological and laboratory evaluations demonstrated CR, bone marrow (BM) biopsy and aspirate were performed 8 weeks later for confirmation; BM sample: normocellular for age, \<30% of the cells being lymphocytes (Lym) and lymphoid nodules (LN) absent was considered as a confirmed CR.
Time frame: Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)
Percentage of Participants With BOR of Partial Response (PR)
PR was achieved if all of the following criteria were met: a)≥50% decrease in Lym count from the baseline value, b)≥50% reduction in LD by CT scan, c)≥50% reduction in size of liver/spleen by PE/CT scan and at least 1 of the following for a minimum of 8 weeks: i. Leuk ≥1.5×10\^9/L or 50% improvement over baseline, ii. Plat \>100×10\^9/L or 50% improvement over baseline and iii. Hb \>11.0 g/dL or 50% improvement over baseline without transfusion. Participants who fulfilled criteria for CR with persistent anemia/thrombocytopenia were considered in PRs. CR was achieved if all of the criteria were fulfilled for ≥8 weeks: a)Absence of LD by PE and CT scan, b)No HM/SM by PE/CT, c)Absence of B symptoms, d)Normal CBC, and e)BM biopsy: normocellular for age, \<30% of the cells being Lym and LN absent.
Time frame: Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)
Percentage of Participants With BOR of Nodular Partial Response (nPR)
CR was achieved if all of the following criteria were met for ≥8 weeks: a)Absence of LD by PE and CT scan, b)No HM/SM by PE/CT scan, c)Absence of B symptoms, d)Normal CBC, and e)BM biopsy: normocellular for age, \<30% of the cells being Lym and LN absent. Participants with nPR were those who satisfied all of the CR criteria except for the BM, where LN could be identified histologically.
Time frame: Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)
Percentage of Participants With BOR of Progressive Disease (PD)
PD is considered if 1 of the following criteria is met: a)≥50% increase in sum of the products of ≥2 lymph nodes compared to their smallest size (at least one ≥2 cm in diameter) or appearance of new lymph nodes/extranodal lesions, b)≥50% increase in the size of hepatosplenomegaly (HSM) as determined by PE/CT scan; appearance of palpable HM/SM that was not previously present, c)≥50% increase in the absolute number of circulating Lym to ≥5×10\^9/L, d)Transformation to a more aggressive histology. Symptomatic deterioration (evident in clinical symptoms but not supported by tumor assessments), in such cases, the determination of clinical progression was based on symptomatic deterioration.
Time frame: Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)
Percentage of Participants With BOR of Stable Disease (SD)
Participants without CR/PR or PD were considered having a tumor response of SD. CR: a) Absence of LD by PE and CT, b) No HM/SM by PE/CT, c) Absence of B symptoms, d) Normal CBC, and e) BM biopsy: normocellular for age, \<30% of the cells being Lym and LN absent. PR: a) ≥50% decrease in Lym count from baseline, b) ≥50% reduction in LD, c) ≥50% reduction in size of liver/spleen by PE/CT and ≥1 of the following for at least 8 weeks: i. Leuk ≥1.5×10\^9/L or 50% improvement over baseline, ii. Plat \>100×10\^9/L or 50% improvement over baseline and iii. Hb \>11.0 g/dL or 50% improvement over baseline without transfusion. PD: a) ≥50% increase in sum of the products of ≥2 lymph nodes compared to their smallest size or appearance of new lymph nodes/extranodal lesions, or b) ≥50% increase in the size of HSM; new appearance of palpable HM/SM, or c) ≥50% increase in the absolute number of circulating Lym to ≥5×10\^9/L, or d) Transformation to a more aggressive histology.
Time frame: Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)
Percentage of Participants With Objective Response (CR or PR)
Objective response was defined as a tumor response of CR or PR. CR was achieved if all of the criteria were met for ≥8 weeks: a)Absence of LD by PE and CT scan, b)No HM/SM by PE/CT scan, c)Absence of B symptoms, d)Normal CBC, and e)BM biopsy: normocellular for age, \<30% of the cells being Lym and LN absent. PR was achieved if all of the criteria were met: a)≥50% decrease in Lymp count from the baseline value, b)≥50% reduction in LD by CT scan, c)≥50% reduction in size of liver/spleen by PE/CT scan and at least 1 of the following for a minimum of 8 weeks: i. Leuk ≥1.5×10\^9/L or 50% improvement over baseline, ii. Plat \>100×10\^9/L or 50% improvement over baseline and iii. Hb \>11.0 g/dL or 50% improvement over baseline without transfusion. Participants who fulfilled criteria for CR with persistent anemia/thrombocytopenia were considered PRs.
Time frame: Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)
Percentage of Participant With Disease Progression or Death
PD is considered if 1 of the following criteria is met: a)≥50% increase in sum of the products of ≥2 lymph nodes compared to their smallest size (at least one ≥2 cm in diameter) or appearance of new lymph nodes/extranodal lesions, b)≥50% increase in the size of HSM as determined by PE/CT scan; appearance of palpable HM/SM that was not previously present, c)≥50% increase in the absolute number of circulating Lym to ≥5×10\^9/L, d)Transformation to a more aggressive histology. Symptomatic deterioration (evident in clinical symptoms but not supported by tumor assessments), in such cases, the determination of clinical progression was based on symptomatic deterioration.
Time frame: Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)
Progression Free Survival (PFS) Time
PFS was defined as the interval (in days) from trial treatment start date to earlier of the date of first tumor response assessment of PD or date of death by any cause. Participants who experienced none of these events or who were lost to follow-up at the time of analysis were censored on last date when they were assessed for tumor response. PD is considered if 1 of the following criteria is met: a)≥50% increase in sum of products of ≥2 lymph nodes compared to their smallest size (at least one ≥2 cm in diameter) or appearance of new lymph nodes/extranodal lesions, b)≥50% increase in the size of HSM as determined by PE/CT; appearance of palpable HM/SM that was not previously present, c)≥50% increase in the number of circulating Lym to ≥5×10\^9/L, d)Transformation to a more aggressive histology. Symptomatic deterioration (evident in clinical symptoms but not supported by tumor assessments), in such cases, the determination of clinical progression was based on symptomatic deterioration.
Time frame: Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)
Disease Free Survival (DFS) Time
DFS time was defined as interval (in days) from first tumor response of CR to date of first tumor response of PD, or date of death by any cause. Participants who experienced none of these events or who were lost to follow-up at the time of analysis were censored on last date when they were assessed for tumor response. CR: a) Absence of LD by PE and CT, b) No HM/SM by PE/CT, c) Absence of B symptoms, d) Normal CBC, and e) BM biopsy: normocellular for age, \<30% of the cells being Lym and LN absent. PD: a) ≥50% increase in sum of the products of ≥2 lymph nodes compared to their smallest size or appearance of new lymph nodes/extranodal lesions, or b) ≥50% increase in the size of HSM; new appearance of palpable HM/SM, or c) ≥50% increase in the absolute number of circulating Lym to ≥5×10\^9/L, or d) Transformation to a more aggressive histology.
Time frame: Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)
Duration of Response (DoR)
DoR: defined as interval (in days) from first tumor response (of CR/PR/nPR) to earlier of date of PD/death. Participants without PD/death or who were lost to follow-up were censored. CR: a)Absence of LD by PE and CT, b)No HM/SM by PE/CT, c)Absence of B symptoms, d)Normal CBC, and e)BM biopsy: normocellular for age, \<30% of the cells being Lym and LN absent. PR: a)≥50% decrease in Lym count from baseline value, b)≥50% reduction in LD, c)≥50% reduction in size of liver/spleen by PE/CT scan and d)Leuk, Plat and Hb ≥1.5×10\^9/L, \>100×10\^9/L and \>11.0 g/dL, respectively or 50% improvement (of all the 3) over baseline value. nPR: participants who satisfied all of CR criteria except for BM, where LN could be identified. PD: a)≥50% increase in sum of the products of ≥2 lymph nodes or appearance of new lymph nodes/extranodal lesions, or b)≥50% increase in size of HSM; new appearance of palpable HM/SM, or c)≥50% increase in number of Lym, or d)Transformation to a more aggressive histology.
Time frame: Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)
Percentage of Participants Who Died
Time frame: Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)
Overall Survival (OS) Time
This was defined as the interval (number of days) from the trial treatment start date to the date of death by any cause. Participants who were alive at the time of the analysis were censored at the date of the last follow-up assessment.
Time frame: Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)
Percentage of Participants Who Achieved Minimal Residual Disease (MRD) Negativity
MRD negativity was defined by the absence of tumor cells in bone marrow, using 4-color flow cytometry. MRD was assessed in participants with a confirmed CR. CR was achieved if all of the following criteria were met for ≥8 weeks: a)Absence of LD by PE and CT scan, b)No HM/SM by PE/CT scan, c)Absence of B symptoms, d)Normal CBC, and e)BM biopsy: normocellular for age, \<30% of the cells being Lym and LN absent.
Time frame: Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)
Mean Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Scores
EORTC QLQ-C30: included global health status (GHS)/quality of life (QOL), functional scales (physical, role, cognitive, emotional, and social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulties). Most questions used a 4- point scale (1 'Not at All' to 4 'Very Much'); 2 questions used a 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores were averaged and transformed to 0-100 scale; a higher score for Global Qol/functional scales=better level of QoL/functioning, or a higher score for symptom scale=greater degree of symptoms.
Time frame: Baseline, Day 1 of Cycles 5 and 11, end of follow-up (FU) (24 month [m] FU visit, up to approximately 3 years)
| Milestone | Rituximab + Chlorambucil |
|---|---|
| Started | 100 |
| Completed | 51 |
| Not completed | 49 |
| Withdrew: Adverse event/serious adverse event | 25 |
| Withdrew: Physician decision | 15 |
| Withdrew: Disease progression | 3 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Other | 5 |
| Milestone | Rituximab + Chlorambucil |
|---|---|
| Started | 98 |
| Completed | 33 |
| Not completed | 65 |
| Withdrew: Adverse event/serious adverse event | 1 |
| Withdrew: Disease progression | 57 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Other | 6 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 56 days from the beginning of the last treatment cycle that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs as well as non-serious AEs.
| percentage of participants | Rituximab + Chlorambucil |
|---|---|
| Percentage of Participants With Treatment-Emergent Adverse Events (AEs) | 99 |
Clinical CR was achieved if all of the following criteria were met: a)Absence of lymphadenopathy (LD) by physical examination (PE) and Computed Tomography (CT) scan (all lymph nodes less than \[\<\] 1.5 centimeters \[cm\] in diameter), b)No hepatomegaly (HM)/splenomegaly (SM) by PE/CT scan, c)Absence of B symptoms (unexplained fever greater than \[\>\] 38 degrees \[°\] Centigrade \[C\], drenching night sweats/\>10 percent \[%\] body weight loss in the last 6 months), d)Normal Complete Blood Count (CBC) (i. Leukocytes (Leuk) greater than or equal to \[≥\] 1.5×10\^9 per liter (/L), ii. Platelets (Plat) \>100×10\^9/L, and iii. Haemoglobin (Hb) \>11.0 grams per deciliter \[g/dL\]) and e)Once clinical, radiological and laboratory evaluations demonstrated CR, bone marrow (BM) biopsy and aspirate were performed 8 weeks later for confirmation; BM sample: normocellular for age, \<30% of the cells being lymphocytes (Lym) and lymphoid nodules (LN) absent was considered as a confirmed CR.
| percentage of participants | Rituximab + Chlorambucil |
|---|---|
| Clinical CR | 37.0 |
| Confirmed CR | 10.0 |
| Clinical CR or Confirmed CR | 47.0 |
PR was achieved if all of the following criteria were met: a)≥50% decrease in Lym count from the baseline value, b)≥50% reduction in LD by CT scan, c)≥50% reduction in size of liver/spleen by PE/CT scan and at least 1 of the following for a minimum of 8 weeks: i. Leuk ≥1.5×10\^9/L or 50% improvement over baseline, ii. Plat \>100×10\^9/L or 50% improvement over baseline and iii. Hb \>11.0 g/dL or 50% improvement over baseline without transfusion. Participants who fulfilled criteria for CR with persistent anemia/thrombocytopenia were considered in PRs. CR was achieved if all of the criteria were fulfilled for ≥8 weeks: a)Absence of LD by PE and CT scan, b)No HM/SM by PE/CT, c)Absence of B symptoms, d)Normal CBC, and e)BM biopsy: normocellular for age, \<30% of the cells being Lym and LN absent.
| percentage of participants | Rituximab + Chlorambucil |
|---|---|
| Percentage of Participants With BOR of Partial Response (PR) | 68.0 |
CR was achieved if all of the following criteria were met for ≥8 weeks: a)Absence of LD by PE and CT scan, b)No HM/SM by PE/CT scan, c)Absence of B symptoms, d)Normal CBC, and e)BM biopsy: normocellular for age, \<30% of the cells being Lym and LN absent. Participants with nPR were those who satisfied all of the CR criteria except for the BM, where LN could be identified histologically.
| percentage of participants | Rituximab + Chlorambucil |
|---|---|
| Percentage of Participants With BOR of Nodular Partial Response (nPR) | 6.0 |
PD is considered if 1 of the following criteria is met: a)≥50% increase in sum of the products of ≥2 lymph nodes compared to their smallest size (at least one ≥2 cm in diameter) or appearance of new lymph nodes/extranodal lesions, b)≥50% increase in the size of hepatosplenomegaly (HSM) as determined by PE/CT scan; appearance of palpable HM/SM that was not previously present, c)≥50% increase in the absolute number of circulating Lym to ≥5×10\^9/L, d)Transformation to a more aggressive histology. Symptomatic deterioration (evident in clinical symptoms but not supported by tumor assessments), in such cases, the determination of clinical progression was based on symptomatic deterioration.
| percentage of participants | Rituximab + Chlorambucil |
|---|---|
| Percentage of Participants With BOR of Progressive Disease (PD) | 4.0 |
Participants without CR/PR or PD were considered having a tumor response of SD. CR: a) Absence of LD by PE and CT, b) No HM/SM by PE/CT, c) Absence of B symptoms, d) Normal CBC, and e) BM biopsy: normocellular for age, \<30% of the cells being Lym and LN absent. PR: a) ≥50% decrease in Lym count from baseline, b) ≥50% reduction in LD, c) ≥50% reduction in size of liver/spleen by PE/CT and ≥1 of the following for at least 8 weeks: i. Leuk ≥1.5×10\^9/L or 50% improvement over baseline, ii. Plat \>100×10\^9/L or 50% improvement over baseline and iii. Hb \>11.0 g/dL or 50% improvement over baseline without transfusion. PD: a) ≥50% increase in sum of the products of ≥2 lymph nodes compared to their smallest size or appearance of new lymph nodes/extranodal lesions, or b) ≥50% increase in the size of HSM; new appearance of palpable HM/SM, or c) ≥50% increase in the absolute number of circulating Lym to ≥5×10\^9/L, or d) Transformation to a more aggressive histology.
| percentage of participants | Rituximab + Chlorambucil |
|---|---|
| Percentage of Participants With BOR of Stable Disease (SD) | 11.0 |
Objective response was defined as a tumor response of CR or PR. CR was achieved if all of the criteria were met for ≥8 weeks: a)Absence of LD by PE and CT scan, b)No HM/SM by PE/CT scan, c)Absence of B symptoms, d)Normal CBC, and e)BM biopsy: normocellular for age, \<30% of the cells being Lym and LN absent. PR was achieved if all of the criteria were met: a)≥50% decrease in Lymp count from the baseline value, b)≥50% reduction in LD by CT scan, c)≥50% reduction in size of liver/spleen by PE/CT scan and at least 1 of the following for a minimum of 8 weeks: i. Leuk ≥1.5×10\^9/L or 50% improvement over baseline, ii. Plat \>100×10\^9/L or 50% improvement over baseline and iii. Hb \>11.0 g/dL or 50% improvement over baseline without transfusion. Participants who fulfilled criteria for CR with persistent anemia/thrombocytopenia were considered PRs.
| percentage of participants | Rituximab + Chlorambucil |
|---|---|
| Percentage of Participants With Objective Response (CR or PR) | 84.0 (75.3 to 90.6) |
PD is considered if 1 of the following criteria is met: a)≥50% increase in sum of the products of ≥2 lymph nodes compared to their smallest size (at least one ≥2 cm in diameter) or appearance of new lymph nodes/extranodal lesions, b)≥50% increase in the size of HSM as determined by PE/CT scan; appearance of palpable HM/SM that was not previously present, c)≥50% increase in the absolute number of circulating Lym to ≥5×10\^9/L, d)Transformation to a more aggressive histology. Symptomatic deterioration (evident in clinical symptoms but not supported by tumor assessments), in such cases, the determination of clinical progression was based on symptomatic deterioration.
| percentage of participants | Rituximab + Chlorambucil |
|---|---|
| Percentage of Participant With Disease Progression or Death | 68.0 |
PFS was defined as the interval (in days) from trial treatment start date to earlier of the date of first tumor response assessment of PD or date of death by any cause. Participants who experienced none of these events or who were lost to follow-up at the time of analysis were censored on last date when they were assessed for tumor response. PD is considered if 1 of the following criteria is met: a)≥50% increase in sum of products of ≥2 lymph nodes compared to their smallest size (at least one ≥2 cm in diameter) or appearance of new lymph nodes/extranodal lesions, b)≥50% increase in the size of HSM as determined by PE/CT; appearance of palpable HM/SM that was not previously present, c)≥50% increase in the number of circulating Lym to ≥5×10\^9/L, d)Transformation to a more aggressive histology. Symptomatic deterioration (evident in clinical symptoms but not supported by tumor assessments), in such cases, the determination of clinical progression was based on symptomatic deterioration.
| days | Rituximab + Chlorambucil |
|---|---|
| Progression Free Survival (PFS) Time | 716.5 (500.0 to 784.0) |
DFS time was defined as interval (in days) from first tumor response of CR to date of first tumor response of PD, or date of death by any cause. Participants who experienced none of these events or who were lost to follow-up at the time of analysis were censored on last date when they were assessed for tumor response. CR: a) Absence of LD by PE and CT, b) No HM/SM by PE/CT, c) Absence of B symptoms, d) Normal CBC, and e) BM biopsy: normocellular for age, \<30% of the cells being Lym and LN absent. PD: a) ≥50% increase in sum of the products of ≥2 lymph nodes compared to their smallest size or appearance of new lymph nodes/extranodal lesions, or b) ≥50% increase in the size of HSM; new appearance of palpable HM/SM, or c) ≥50% increase in the absolute number of circulating Lym to ≥5×10\^9/L, or d) Transformation to a more aggressive histology.
| days | Rituximab + Chlorambucil |
|---|---|
| Disease Free Survival (DFS) Time | 855.0 (290.0 to 855.0) |
DoR: defined as interval (in days) from first tumor response (of CR/PR/nPR) to earlier of date of PD/death. Participants without PD/death or who were lost to follow-up were censored. CR: a)Absence of LD by PE and CT, b)No HM/SM by PE/CT, c)Absence of B symptoms, d)Normal CBC, and e)BM biopsy: normocellular for age, \<30% of the cells being Lym and LN absent. PR: a)≥50% decrease in Lym count from baseline value, b)≥50% reduction in LD, c)≥50% reduction in size of liver/spleen by PE/CT scan and d)Leuk, Plat and Hb ≥1.5×10\^9/L, \>100×10\^9/L and \>11.0 g/dL, respectively or 50% improvement (of all the 3) over baseline value. nPR: participants who satisfied all of CR criteria except for BM, where LN could be identified. PD: a)≥50% increase in sum of the products of ≥2 lymph nodes or appearance of new lymph nodes/extranodal lesions, or b)≥50% increase in size of HSM; new appearance of palpable HM/SM, or c)≥50% increase in number of Lym, or d)Transformation to a more aggressive histology.
| days | Rituximab + Chlorambucil |
|---|---|
| Duration of Response (DoR) | 645.0 (561.0 to 758.0) |
| percentage of participants | Rituximab + Chlorambucil |
|---|---|
| Percentage of Participants Who Died | 15.0 |
This was defined as the interval (number of days) from the trial treatment start date to the date of death by any cause. Participants who were alive at the time of the analysis were censored at the date of the last follow-up assessment.
| percentage of participants | Rituximab + Chlorambucil |
|---|---|
| Overall Survival (OS) Time | NA (NA to NA) |
MRD negativity was defined by the absence of tumor cells in bone marrow, using 4-color flow cytometry. MRD was assessed in participants with a confirmed CR. CR was achieved if all of the following criteria were met for ≥8 weeks: a)Absence of LD by PE and CT scan, b)No HM/SM by PE/CT scan, c)Absence of B symptoms, d)Normal CBC, and e)BM biopsy: normocellular for age, \<30% of the cells being Lym and LN absent.
| percentage of participants | Rituximab + Chlorambucil |
|---|---|
| Percentage of Participants Who Achieved Minimal Residual Disease (MRD) Negativity | 0.0 |
EORTC QLQ-C30: included global health status (GHS)/quality of life (QOL), functional scales (physical, role, cognitive, emotional, and social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulties). Most questions used a 4- point scale (1 'Not at All' to 4 'Very Much'); 2 questions used a 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores were averaged and transformed to 0-100 scale; a higher score for Global Qol/functional scales=better level of QoL/functioning, or a higher score for symptom scale=greater degree of symptoms.
| units on scale | Rituximab + Chlorambucil |
|---|---|
| GHS/QoL score-baseline (n=91) | 65.7 ± 21.8 |
| CFB in GHS/QoL Score-Cycle 5 (n=59) | 6.4 ± 21.7 |
| CFB in GHS/QoL Score-Cycle 11 (n=40) | 6.2 ± 16.9 |
| CFB in GHS/QoL Score-24m FU (n=17) | 2.0 ± 15.2 |
| Physical functioning score-baseline (n=91) | 77.0 ± 22.3 |
| CFB in physical functioning score-Cycle 5 (n=59) | 1.0 ± 15.3 |
| CFB in physical functioning score-Cycle 11 (n=40) | 3.4 ± 22.0 |
| CFB in physical functioning score-24m FU (n=17) | -2.0 ± 10.2 |
| Role functioning score-baseline (n=91) | 73.4 ± 31.6 |
| CFB in role functioning score-Cycle 5 (n=59) | 0.0 ± 28.9 |
| CFB in role functioning score-Cycle 11 (n=40) | 3.8 ± 32.1 |
| CFB in role functioning score-24m FU (n=17) | 3.9 ± 20.0 |
| Emotional functioning score-baseline (n=91) | 82.5 ± 18.1 |
| CFB in emotional functioning score-Cycle 5 (n=59) | 1.0 ± 16.5 |
| CFB in emotional functioning score-Cycle 11 (n=40) | -0.1 ± 18.1 |
| CFB in emotional functioning score-24m FU (n=17) | 0.5 ± 17.3 |
| Cognitive functioning score-baseline (n=91) | 84.1 ± 19.1 |
| CFB in cognitive functioning score-Cycle 5 (n=59) | -1.9 ± 15.4 |
| CFB in cognitive functioning-Cycle 11 (n=40) | -0.4 ± 18.8 |
| CFB in cognitive functioning-24m FU (n=17) | 5.2 ± 18.0 |
| Social functioning score-baseline (n=91) | 82.2 ± 24.2 |
| CFB in social functioning score-Cycle 5 (n=59) | 2.5 ± 22.5 |
| CFB in social functioning score-Cycle 11 (n=40) | 0.0 ± 27.9 |
| CFB in social functioning score-at 24m FU (n=17) | 5.2 ± 19.9 |
| Fatigue score-baseline (n=91) | 33.4 ± 25.7 |
| CFB in fatigue score-Cycle 5 (n=59) | -1.4 ± 24.9 |
| CFB in fatigue score-Cycle 11 (n=40) | -6.1 ± 27.7 |
| CFB in fatigue score-24m FU (n=17) | -5.6 ± 22.2 |
| Nausea/vomiting score-baseline (n=91) | 6.2 ± 16.2 |
| CFB in nausea/vomiting score-Cycle 5 (n=59) | 1.7 ± 20.9 |
| CFB in nausea/vomiting score-Cycle 11 (n=40) | 0.4 ± 20.8 |
| CFB in nausea/vomiting score-24m FU (n=17) | -2.9 ± 8.8 |
| Pain score-baseline (n=91) | 17.8 ± 27.0 |
| CFB in pain score-Cycle 5 (n=59) | -3.4 ± 28.8 |
| CFB in pain score-Cycle 11 (n=40) | -1.3 ± 33.2 |
| CFB in pain score-24m FU (n=17) | 0.0 ± 31.2 |
Collected over First administration of study treatment up to 56 days after the beginning of the last treatment cycle (up to 365 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab + Chlorambucil | — | 39/100 (39%) | 97/100 (97%) |
| Event | Rituximab + Chlorambucil |
|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 5/100 |
| Neutropenic sepsisInfections and infestations | 4/100 |
| Infusion related reactionGeneral disorders | 3/100 |
| PneumoniaInfections and infestations | 2/100 |
| PyrexiaGeneral disorders | 2/100 |
| VomitingGastrointestinal disorders | 2/100 |
| Back painMusculoskeletal and connective tissue disorders | 2/100 |
| Joint swellingMusculoskeletal and connective tissue disorders | 2/100 |
| Cytokine release syndromeImmune system disorders | 2/100 |
| Anal infectionInfections and infestations | 1/100 |
| Event | Rituximab + Chlorambucil |
|---|---|
| NauseaGastrointestinal disorders | 51/100 |
| LymphopeniaBlood and lymphatic system disorders | 41/100 |
| NeutropeniaBlood and lymphatic system disorders | 41/100 |
| FatigueGeneral disorders | 31/100 |
| PyrexiaGeneral disorders | 27/100 |
| LeukopeniaBlood and lymphatic system disorders | 23/100 |
| VomitingGastrointestinal disorders | 22/100 |
| AnaemiaBlood and lymphatic system disorders | 20/100 |
| CoughRespiratory, thoracic and mediastinal disorders | 20/100 |
| ThrombocytopeniaBlood and lymphatic system disorders | 19/100 |
Full analysis set (FAS) comprised all participants recruited into the study and known to have received at least one dose of study treatment.
| Age, Continuous(years) | Rituximab + Chlorambucil |
|---|---|
| Mean | 69.5 ± 8.3 |
| Sex: Female, Male(Participants) | Rituximab + Chlorambucil |
|---|---|
| Female | 34 |
| Male | 66 |
Plan to share: No
The record gives a start of Nov 2007, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2016, 4 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rituximab · Chlorambucil
Leukemia, Lymphocytic, Chronic, B-Cell →